Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26048460 | 0.85 | KDM4E (0.36) | FOLH1ALDH1A1HTR7CHRM1TBXA2R | |
| SCHEMBL24325844 | 0.84 | FOLH1 (0.34) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL28966306 | 0.82 | FOLH1 (0.36) | FOLH1SMN1; SMN2ALDH1A1HTR7CHRM1 | |
| SCHEMBL10156632 | 0.81 | ALDH1A1 (0.37) | FOLH1ALDH1A1HSD17B10LMNAHTR7 | |
| SCHEMBL21791312 | 0.80 | ELANE (0.37) | FOLH1SMN1; SMN2ALDH1A1HTR7CHRM1 | |
| SCHEMBL4479703 | 0.79 | FOLH1 (0.38) | FOLH1ALDH1A1HTR7CHRM1TBXA2R | |
| SCHEMBL10193622 | 0.79 | ALDH1A1 (0.36) | FOLH1ALDH1A1HSD17B10LMNAHTR7 | |
| SCHEMBL22336901 | 0.79 | FOLH1 (0.33) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL15413216 | 0.78 | FOLH1 (0.38) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL24966594 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1HSD17B10LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | FOLH1 645/4885SMN1; SMN2 3927/4885ALDH1A1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.